Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innoviva (INVA) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Innoviva (INVA) over the last 17 years, with Sep 2025 value amounting to $476.5 million.

  • Innoviva's Cash & Equivalents rose 82.83% to $476.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $476.5 million, marking a year-over-year increase of 82.83%. This contributed to the annual value of $305.0 million for FY2024, which is 57.59% up from last year.
  • Per Innoviva's latest filing, its Cash & Equivalents stood at $476.5 million for Q3 2025, which was up 19.87% from $397.5 million recorded in Q2 2025.
  • Innoviva's 5-year Cash & Equivalents high stood at $476.5 million for Q3 2025, and its period low was $43.3 million during Q2 2021.
  • Moreover, its 3-year median value for Cash & Equivalents was $217.0 million (2024), whereas its average is $258.6 million.
  • As far as peak fluctuations go, Innoviva's Cash & Equivalents slumped by 89.53% in 2021, and later soared by 555.45% in 2022.
  • Over the past 5 years, Innoviva's Cash & Equivalents (Quarterly) stood at $201.5 million in 2021, then spiked by 44.42% to $291.0 million in 2022, then slumped by 33.51% to $193.5 million in 2023, then soared by 57.59% to $305.0 million in 2024, then soared by 82.83% to $476.5 million in 2025.
  • Its Cash & Equivalents stands at $476.5 million for Q3 2025, versus $397.5 million for Q2 2025 and $319.1 million for Q1 2025.